US Stock MarketDetailed Quotes

LABP Landos Biopharma

Watchlist
  • 22.2050
  • -0.1250-0.56%
Close May 13 16:00 ET
69.41MMarket Cap-5551P/E (TTM)

Landos Biopharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-4.01%-8.5M
55.22%-20.48M
-36.03%-4.97M
70.58%-2.23M
71.61%-5.11M
50.49%-8.17M
-68.97%-45.73M
69.70%-3.65M
36.06%-7.57M
-291.46%-18M
Net income from continuing operations
-47.45%-8.9M
44.15%-21.94M
-16.95%-6.12M
25.79%-5.86M
65.24%-3.92M
59.41%-6.03M
-2.22%-39.28M
73.97%-5.23M
37.35%-7.9M
-375.42%-11.28M
Operating gains losses
----
----
----
----
----
----
-1,066.67%-210K
-163.00%-63K
6.77%-124K
---14K
Depreciation and amortization
----
--0
--0
--0
----
----
194.39%577K
--0
--0
348.00%224K
Other non cash items
----
----
----
----
----
----
--91K
---46K
--0
--0
Change In working capital
105.81%139K
104.40%443K
-33.01%905K
1,407.72%3.39M
81.31%-1.46M
29.06%-2.39M
-271.01%-10.07M
-75.41%1.35M
-331.67%-259K
-291.50%-7.79M
-Change in prepaid assets
-7.34%-351K
-13.25%360K
-66.10%219K
8.12%839K
-129.56%-371K
85.54%-327K
144.34%415K
162.00%646K
-43.19%776K
236.46%1.26M
-Change in payables and accrued expense
114.78%187K
77.53%-2.13M
-15.92%243K
106.83%103K
76.60%-1.21M
58.98%-1.27M
-322.21%-9.47M
-89.52%289K
-168.15%-1.51M
-309.27%-5.17M
-Change in other current liabilities
137.88%303K
317.72%2.21M
6.49%443K
418.01%2.45M
103.20%124K
-140.53%-800K
-139.63%-1.02M
-88.99%416K
154.63%472K
-416.31%-3.88M
Cash from discontinued investing activities
Operating cash flow
-4.01%-8.5M
55.26%-20.48M
-34.33%-4.97M
70.58%-2.23M
71.61%-5.11M
50.49%-8.17M
-69.14%-45.77M
69.32%-3.7M
36.06%-7.57M
-291.46%-18M
Investing cash flow
Cash flow from continuing investing activities
0
-89.50%7.78M
-99.45%63K
-96.32%634K
-84.64%3.97M
-84.09%3.1M
226.15%74.06M
538.70%11.47M
58.91%17.21M
3,518.32%25.87M
Net PPE purchase and sale
----
--0
--0
--0
----
----
152.05%229K
70.27%63K
152.27%138K
123.49%35K
Net investment purchase and sale
--0
-89.47%7.78M
-99.45%63K
-96.29%634K
-84.62%3.97M
-84.09%3.1M
226.71%73.83M
548.55%11.41M
53.89%17.07M
2,890.28%25.84M
Cash from discontinued investing activities
Investing cash flow
--0
-89.50%7.78M
-99.45%63K
-96.32%634K
-84.64%3.97M
-84.09%3.1M
226.15%74.06M
538.70%11.47M
58.91%17.21M
3,518.32%25.87M
Financing cash flow
Cash flow from continuing financing activities
0
13.57M
0
0
-99K
13.67M
0
0
0
0
Net common stock issuance
--0
--13.57M
--16.57M
---16.57M
---99K
--13.67M
--0
--0
--0
--0
Cash from discontinued financing activities
Financing cash flow
--0
--13.57M
--0
--0
---99K
--13.67M
--0
--0
--0
--0
Net cash flow
Beginning cash position
2.48%37.55M
341.18%36.64M
47.02%42.46M
128.93%44.05M
300.82%45.24M
341.18%36.64M
243.75%8.31M
61.40%28.88M
2.96%19.24M
31.68%11.29M
Current changes in cash
-198.81%-8.5M
-96.94%865K
-163.12%-4.91M
-116.54%-1.59M
-115.68%-1.24M
186.28%8.6M
384.40%28.29M
180.65%7.77M
1,313.98%9.64M
-22.16%7.87M
Effect of exchange rate changes
-25.00%3K
-4.35%44K
75.00%-3K
--3K
-49.37%40K
119.05%4K
-6.12%46K
-124.49%-12K
--0
--79K
End cash Position
-35.78%29.05M
2.48%37.55M
2.48%37.55M
47.02%42.46M
128.93%44.05M
300.82%45.24M
341.18%36.64M
341.18%36.64M
61.40%28.88M
2.96%19.24M
Free cash flow
-4.01%-8.5M
55.27%-20.48M
-34.33%-4.97M
70.58%-2.23M
71.61%-5.11M
50.51%-8.17M
-66.46%-45.78M
69.23%-3.7M
37.45%-7.57M
-294.54%-18M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -4.01%-8.5M55.22%-20.48M-36.03%-4.97M70.58%-2.23M71.61%-5.11M50.49%-8.17M-68.97%-45.73M69.70%-3.65M36.06%-7.57M-291.46%-18M
Net income from continuing operations -47.45%-8.9M44.15%-21.94M-16.95%-6.12M25.79%-5.86M65.24%-3.92M59.41%-6.03M-2.22%-39.28M73.97%-5.23M37.35%-7.9M-375.42%-11.28M
Operating gains losses -------------------------1,066.67%-210K-163.00%-63K6.77%-124K---14K
Depreciation and amortization ------0--0--0--------194.39%577K--0--0348.00%224K
Other non cash items --------------------------91K---46K--0--0
Change In working capital 105.81%139K104.40%443K-33.01%905K1,407.72%3.39M81.31%-1.46M29.06%-2.39M-271.01%-10.07M-75.41%1.35M-331.67%-259K-291.50%-7.79M
-Change in prepaid assets -7.34%-351K-13.25%360K-66.10%219K8.12%839K-129.56%-371K85.54%-327K144.34%415K162.00%646K-43.19%776K236.46%1.26M
-Change in payables and accrued expense 114.78%187K77.53%-2.13M-15.92%243K106.83%103K76.60%-1.21M58.98%-1.27M-322.21%-9.47M-89.52%289K-168.15%-1.51M-309.27%-5.17M
-Change in other current liabilities 137.88%303K317.72%2.21M6.49%443K418.01%2.45M103.20%124K-140.53%-800K-139.63%-1.02M-88.99%416K154.63%472K-416.31%-3.88M
Cash from discontinued investing activities
Operating cash flow -4.01%-8.5M55.26%-20.48M-34.33%-4.97M70.58%-2.23M71.61%-5.11M50.49%-8.17M-69.14%-45.77M69.32%-3.7M36.06%-7.57M-291.46%-18M
Investing cash flow
Cash flow from continuing investing activities 0-89.50%7.78M-99.45%63K-96.32%634K-84.64%3.97M-84.09%3.1M226.15%74.06M538.70%11.47M58.91%17.21M3,518.32%25.87M
Net PPE purchase and sale ------0--0--0--------152.05%229K70.27%63K152.27%138K123.49%35K
Net investment purchase and sale --0-89.47%7.78M-99.45%63K-96.29%634K-84.62%3.97M-84.09%3.1M226.71%73.83M548.55%11.41M53.89%17.07M2,890.28%25.84M
Cash from discontinued investing activities
Investing cash flow --0-89.50%7.78M-99.45%63K-96.32%634K-84.64%3.97M-84.09%3.1M226.15%74.06M538.70%11.47M58.91%17.21M3,518.32%25.87M
Financing cash flow
Cash flow from continuing financing activities 013.57M00-99K13.67M0000
Net common stock issuance --0--13.57M--16.57M---16.57M---99K--13.67M--0--0--0--0
Cash from discontinued financing activities
Financing cash flow --0--13.57M--0--0---99K--13.67M--0--0--0--0
Net cash flow
Beginning cash position 2.48%37.55M341.18%36.64M47.02%42.46M128.93%44.05M300.82%45.24M341.18%36.64M243.75%8.31M61.40%28.88M2.96%19.24M31.68%11.29M
Current changes in cash -198.81%-8.5M-96.94%865K-163.12%-4.91M-116.54%-1.59M-115.68%-1.24M186.28%8.6M384.40%28.29M180.65%7.77M1,313.98%9.64M-22.16%7.87M
Effect of exchange rate changes -25.00%3K-4.35%44K75.00%-3K--3K-49.37%40K119.05%4K-6.12%46K-124.49%-12K--0--79K
End cash Position -35.78%29.05M2.48%37.55M2.48%37.55M47.02%42.46M128.93%44.05M300.82%45.24M341.18%36.64M341.18%36.64M61.40%28.88M2.96%19.24M
Free cash flow -4.01%-8.5M55.27%-20.48M-34.33%-4.97M70.58%-2.23M71.61%-5.11M50.51%-8.17M-66.46%-45.78M69.23%-3.7M37.45%-7.57M-294.54%-18M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion--------Unqualified Opinion------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg